KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Assets: 2009-2024

Historic Assets for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $4.2 billion.

  • Alnylam Pharmaceuticals' Assets rose 15.38% to $4.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year increase of 15.38%. This contributed to the annual value of $4.2 billion for FY2024, which is 10.71% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Assets of $4.2 billion as of FY2024, which was up 10.71% from $3.8 billion recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Assets ranged from a high of $4.2 billion in FY2024 and a low of $3.4 billion during FY2020.
  • In the last 3 years, Alnylam Pharmaceuticals' Assets had a median value of $3.8 billion in 2023 and averaged $3.9 billion.
  • In the last 5 years, Alnylam Pharmaceuticals' Assets soared by 42.25% in 2020 and then fell by 2.66% in 2022.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Assets stood at $3.4 billion in 2020, then climbed by 6.93% to $3.6 billion in 2021, then decreased by 2.66% to $3.5 billion in 2022, then grew by 7.99% to $3.8 billion in 2023, then increased by 10.71% to $4.2 billion in 2024.